802 related articles for article (PubMed ID: 15801334)
1. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
6. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Heiligenstein JH; Faries DE; Galil N; Dittmann R; Emslie GJ; Kratochvil CJ; Laws HF; Schuh KJ;
Pediatrics; 2002 Dec; 110(6):e75. PubMed ID: 12456942
[TBL] [Abstract][Full Text] [Related]
8. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
[TBL] [Abstract][Full Text] [Related]
9. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Biederman J; Spencer TJ; Newcorn JH; Gao H; Milton DR; Feldman PD; Witte MM
Psychopharmacology (Berl); 2007 Jan; 190(1):31-41. PubMed ID: 17093981
[TBL] [Abstract][Full Text] [Related]
10. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
Hazell P; Zhang S; Wolańczyk T; Barton J; Johnson M; Zuddas A; Danckaerts M; Ladikos A; Benn D; Yoran-Hegesh R; Zeiner P; Michelson D
Eur Child Adolesc Psychiatry; 2006 Mar; 15(2):105-10. PubMed ID: 16523251
[TBL] [Abstract][Full Text] [Related]
11. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Hazell P; Becker K; Nikkanen EA; Trzepacz PT; Tanaka Y; Tabas L; D'Souza DN; Witcher J; Long A; Ponsler G; Dittmann RW
Atten Defic Hyperact Disord; 2009 Dec; 1(2):201-10. PubMed ID: 20234828
[TBL] [Abstract][Full Text] [Related]
12. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Cheng JY; Chen RY; Ko JS; Ng EM
Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
[TBL] [Abstract][Full Text] [Related]
17. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Holzer B; Lopes V; Lehman R
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
Geller D; Donnelly C; Lopez F; Rubin R; Newcorn J; Sutton V; Bakken R; Paczkowski M; Kelsey D; Sumner C
J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1119-1127. PubMed ID: 17712235
[TBL] [Abstract][Full Text] [Related]
19. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Gaillez C; Sorbara F; Perrin E
Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
